#USA #New York #Immunic #Vidofludimus #Relapsing MS

Immunic's Upcoming Virtual R&D Day on Relapsing Multiple Sclerosis

Immunic, Inc. (Nasdaq: IMUX), a cutting-edge biotechnology company, has announced an exciting virtual Research and Development (R&D) day to take place on September 9, 2026. This event will focus on the developments surrounding relapsing multiple sclerosis (MS), a condition that impacts countless individuals worldwide.

The R&D Day will feature a host of key figures from Immunic's management team, including CEO Erik Lundgren and Chief Medical Officer Michael A. Panzara. They will be joined by two distinguished experts in the field: Dr. Amit Bar-Or from the Perelman School of Medicine at the University of Pennsylvania and Dr. Stephen Krieger from the Icahn School of Medicine at Mount Sinai Hospital in New York City. Together, they will share insights related to ongoing research and the future of treatment options available for patients dealing with MS.

Focus on Vidofludimus Calcium

Central to this event will be a discussion surrounding vidofludimus calcium (IMU-838), an innovative oral therapy currently under investigation for its efficacy in treating relapsing MS. This therapy combines two mechanisms—activation of nuclear receptor-related 1 (Nurr1) and selective inhibition of dihydroorotate dehydrogenase (DHODH) to tackle the diverse challenges of inflammation and neurodegeneration associated with MS.

What sets this approach apart is its potential to address persistent unmet needs that traditional anti-inflammatory treatments often overlook. The team aims to demonstrate how the unique properties of vidofludimus calcium could significantly change the landscape of treatment for relapsing MS patients.

Drs. Bar-Or and Krieger will contribute their expertise by discussing the complexities of the MS patient journey, current treatment paradigms, and the existing gaps in medical care that need to be filled to improve patient outcomes.

Event Details

The virtual R&D Day is scheduled for September 9, 2026, from 11:00 AM to 12:30 PM ET, and will be accessible via Zoom. Interested participants can register for the event through the link provided on Immunic's official website.

Background on Immunic

Founded with the vision of pioneering novel therapeutic solutions, Immunic, Inc. seeks to transform the treatment options available for neurological diseases. With vidofludimus calcium in late-stage clinical trials, the future holds promise, with top-line data from the Phase 3 ENSURE trials anticipated by the end of 2026. The company is also set to commence a Phase 3 trial exploring treatment options for progressive MS later this year.

Encouraging results from earlier Phase 2 studies have suggested that this investigational therapy offers not only a favorable safety profile but also therapeutic potential that could reshape patient care in multiple sclerosis.

Conclusion

This R&D Day is crucial as it underlines Immunic's commitment to bring forward progressive treatment options for conditions like relapsing MS. As the event date approaches, anticipation is building within the medical community and among patients hopeful for new advancements in MS therapies. For more information, please visit Immunic's website.

Note: The contents discussed during this event may contain future-facing statements and risks; participants are encouraged to critically assess the information presented as part of the proceedings.